Neumentum, Inc.

neumentum.com

Neumentum is developing and plans to commercialize products that have the potential to effectively treat pain, without the risks of abuse, misuse and diversion seen with opioid analgesics. Neumentum’s lead product candidate, NTM-001 (novel, alcohol-free formulation of ketorolac in a pre-mixed bag for continuous IV infusion), has the potential to treat moderately severe acute pain that requires analgesia at the opioid level for up to 24 hours, usually in a postoperative setting, and to reduce the need for opioids.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

RESEARCH

UCONN STARTUP DIANT BAGS LICENSE FOR CONTINUOUS NANOPARTICLE MANUFACTURING TECH

UConn | November 20, 2020

news image

Consistent assembling has just begun to override customary group handling in the domain of tablet creation. The following region due for an assembling update? Nanoparticle drug conveyance frameworks, one startup thinks—and it's currently prepared to pitch its foundation to drugmakers. The University of Connecticut as of late authorized its ceaseless nanoparticle fabricating innovation to DIANT Pharma, a startup helped to establish by the stage's designers Antonio Cos...

Read More

BUSINESS INSIGHTS

GLAUKOS LICENSES IVEENA’S INVESTIGATIONAL KERATOCONUS THERAPY

iVeena and Glaukos | August 25, 2022

news image

iVeena Delivery Systems Inc. a clinical stage biopharmaceutical company with developmental products in keratoconus and pediatric myopia, has entered into a strategic licensing agreement with Glaukos Corporation that grants Glaukos an exclusive global license to develop and commercialize IVMED-80, a pharmacologic treatment for keratoconus. Keratoconus, a rare corneal disorder, is the leading cause of primary full-thickness corneal transplantation in the United States. IVMED-80 is a...

Read More

PHARMA TECH

WINHEALTH AND IMMEDICA ENTER INTO AN AGREEMENT THAT GIVES WINHEALTH THE RIGHTS TO RAVICTI® IN CHINA AND SEVERAL OTHER ASIA-PACIFIC COUNTRIES

WinHealth | January 04, 2021

news image

Hong Kong WinHealth Pharma Group Co., Ltd. furthermore, Immedica Pharma AB, today declared that they have gone into an understanding under which WinHealth has the restrictive business rights to Ravicti® (Glycerol Phenylbutyrate) for Greater China, South Korea, Singapore, Vietnam , Indonesia, Malaysia , the Philippines and Thailand gets. Ravicti® is shown for the treatment of urea cycle issue (UCD) in Europe and North America, and as a feature of the reported association, W...

Read More

BUSINESS INSIGHTS

ACCORD BIOPHARMA PARTNERS WITH STORYMD TO DELIVER ADVANCED PROSTATE CANCER EDUCATIONAL CONTENT TO CLINICIANS AND PATIENTS

Accord BioPharma | September 21, 2022

news image

Accord BioPharma, the U.S. specialty division of Intas Pharmaceuticals, Ltd., focused on development of oncology, immunology, and critical care therapies, announced today a partnership with StoryMD. The StoryMD platform is a single, unified, personalized digital health information portfolio that curates the most relevant, visually rich content based on a patient's condition. Accord BioPharma has signed on as StoryMD's very first corporate partner, to support StoryMD's advanced prosta...

Read More
news image

RESEARCH

UCONN STARTUP DIANT BAGS LICENSE FOR CONTINUOUS NANOPARTICLE MANUFACTURING TECH

UConn | November 20, 2020

Consistent assembling has just begun to override customary group handling in the domain of tablet creation. The following region due for an assembling update? Nanoparticle drug conveyance frameworks, one startup thinks—and it's currently prepared to pitch its foundation to drugmakers. The University of Connecticut as of late authorized its ceaseless nanoparticle fabricating innovation to DIANT Pharma, a startup helped to establish by the stage's designers Antonio Cos...

Read More
news image

BUSINESS INSIGHTS

GLAUKOS LICENSES IVEENA’S INVESTIGATIONAL KERATOCONUS THERAPY

iVeena and Glaukos | August 25, 2022

iVeena Delivery Systems Inc. a clinical stage biopharmaceutical company with developmental products in keratoconus and pediatric myopia, has entered into a strategic licensing agreement with Glaukos Corporation that grants Glaukos an exclusive global license to develop and commercialize IVMED-80, a pharmacologic treatment for keratoconus. Keratoconus, a rare corneal disorder, is the leading cause of primary full-thickness corneal transplantation in the United States. IVMED-80 is a...

Read More
news image

PHARMA TECH

WINHEALTH AND IMMEDICA ENTER INTO AN AGREEMENT THAT GIVES WINHEALTH THE RIGHTS TO RAVICTI® IN CHINA AND SEVERAL OTHER ASIA-PACIFIC COUNTRIES

WinHealth | January 04, 2021

Hong Kong WinHealth Pharma Group Co., Ltd. furthermore, Immedica Pharma AB, today declared that they have gone into an understanding under which WinHealth has the restrictive business rights to Ravicti® (Glycerol Phenylbutyrate) for Greater China, South Korea, Singapore, Vietnam , Indonesia, Malaysia , the Philippines and Thailand gets. Ravicti® is shown for the treatment of urea cycle issue (UCD) in Europe and North America, and as a feature of the reported association, W...

Read More
news image

BUSINESS INSIGHTS

ACCORD BIOPHARMA PARTNERS WITH STORYMD TO DELIVER ADVANCED PROSTATE CANCER EDUCATIONAL CONTENT TO CLINICIANS AND PATIENTS

Accord BioPharma | September 21, 2022

Accord BioPharma, the U.S. specialty division of Intas Pharmaceuticals, Ltd., focused on development of oncology, immunology, and critical care therapies, announced today a partnership with StoryMD. The StoryMD platform is a single, unified, personalized digital health information portfolio that curates the most relevant, visually rich content based on a patient's condition. Accord BioPharma has signed on as StoryMD's very first corporate partner, to support StoryMD's advanced prosta...

Read More